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ABSTRACT: Antibiotic resistance poses a critical threat to global health care. Alkyl- and 
aryltriazene compounds have found utility as DNA-modifying agents and have been previously 
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assessed as potential anti-cancer therapeutics. However, their potential utility as antimicrobials 
has only recently been appreciated. Therefore, to further investigate the efficacy of these 
compounds as antibiotics, we synthesized a series of forty six diaryltriazene derivatives and 
evaluated their antimicrobial properties. Initial experiments showed activity of some 
diaryltriazene compounds against both methicillin-resistant strains of Staphylococus aureus 
(MRSA) and against Mycobacterium smegmatis with MICs of less than 0.02 and 1 μg/mL. Those 
diaryltriazene compounds with potent anti-staphylococcal and anti-mycobacterial activity were 
inactive as growth inhibitors of mammalian cell lines and yeast. Furthermore, we demonstrated 
that one of the most active anti-MRSA diaryltriazene derivatives was subject to very low 
frequencies of resistance at < 10–9. Whole genome sequencing of resistant isolates identified 
mutations in the enzyme that lysylates phospholipids. This could result in the modification of 
phospholipid metabolism and consequently the characteristics of the staphylococcal cell 
membrane, ultimately modifying the sensitivity of these pathogens to triazene challenge. Our 
work has therefore extended the potential range of triazenes, which could yield novel 
antimicrobials with low levels of resistance. 
 
INTRODUCTION 
Historically the discovery of sulphonamides and β-lactam antibiotics triggered the next 50 
years of research, during which the majority of antimicrobial agents in use today were 
discovered.1 However, the emergence of multidrug-resistance among bacteria including 
Staphylococcus aureus (S. aureus) and other members of the ESKAPE pathogens, and latterly 
extreme drug resistance in these and Mycobacterium tuberculosis (M. tuberculosis; XDRTB), 
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has challenged the effectiveness of antibiotics in the advent of modern medicine. As such, 
antibiotic resistance has become one of the most serious health care problems in the world.2 This 
has been exacerbated by a collapse in antibiotic discovery by global pharma R&D, and resulted 
in a lack of new antibiotics coming to market.3,4 Resistance arises either by alterations to the 
antibiotic target, by the acquisition of antibiotic modifying enzymes, or by reducing the local 
concentration of antibiotic via changes in cell wall permeability or efflux. 
Considering the above, there is an urgent need to develop new effective antibacterial agents 
that circumvent the emergence of resistance.5 Based on our recent research6 we were prompted 
to further explore the antimicrobial activity of 1,3-diaryltriazenes. Triazenes possess a number of 
biological properties, including antifungal,7 anorexic,8 and anticancer activity.9,10 The 
mechanism of action of alkyltriazenes is generally connected the formation of reactive 
diazonium species that are able to alkylate DNA.11,12 
Here we describe the preparation and testing of 46 compounds from the 1,3-diaryltriazene 
family, including 5 compounds containing an isoniazid (INH) moiety, and 31 compounds 
containing a fluorine atom, with the potential to be more biologically active than their non-
fluorinated analogues.13 As a result, several triazenes were identified as possesing potent 
antimicrobial activity towards methicillin resistant S. aureus (MRSA) and M. Smegmatis- a 
model mycobacterial representative of M. tuberculosis. 
 
RESULTS AND DISCUSSION 
Chemistry 
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A series of 46 triazene derivatives 1–19 were prepared according to Scheme 1, and their 
structures are depicted in Figure 1. These include 1,3-diaryltriazenes (1), their N-acyl substituted 
derivatives 2–15, including the carbamate 4e, and triazenide salts 16–19.  
#R4#The selection of substituents at the triazene 1,3-diphenyl rings was mainly focused on 
strongly electro-withdrawing groups, in most cases possessing both –I and –R effects, whereas 
the electron-donating groups were not considered. This selection was stimulated by our recent 
observation on strong in vitro activity of electron-deficient triazenes against M. tuberculosis.6 To 
effectively participate in modulating the electron density, ortho- and/or para- substitution pattern 
relative to the triazene group was selected predominantly.  
#R6#Some 1,3-diaryltriazenes were modified by N-acylation. Nicotinoyl (14), and 
isonicotinoyl (15) derivatives were tentatively considered as potential multi-target hybrid 
compounds of 1,3-diaryltriazenes with isoniazid (INH) structures, potentially releasing the 
isonicotinoyl radical and 1,3-diaryltriazenes. INH is a highly specific first-line TB prodrug, 
which after activation couples isonicotinoyl radical to NADPH and binds irreversibly to enoyl-
AcpM reductase, blocking cell wall synthesis.14 In addition to nicotinoyl (14) and isonicotinoyl 
(15) derivatives, some other acyl analogues 2–13 were considered. Since alkyl triazenes are well 
known as DNA alkylating agents,11,12 this type of derivatives was not investigated from the 
potential genotoxicity reasons. 
 
Scheme 1. Synthesis of compounds 1–19a 
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aReagents: a) NaNO2/HCl;
15 b) isoamyl nitrite;15 c) Na3Co(NO2)6;
16 d) Et3N, ClCOR;
15 e) Et3N, 
HC≡CCO2CH3 or HC≡CCO2C2H5;
17 f) Et3N;
17 g) KOH.17 For a key of substituents, see Figure 1.  
 
 
Figure 1. The structures of 1,3-diaryltriazenes 1, N-acylated 1,3-diaryltriazenes 2–15 and 
triazenide salts 16–19.  
1,3-Diaryltriazenes 1a–h were prepared by treating the appropriately substituted anilines with 
either sodium nitrite in hydrochloric acid, isoamyl nitrite, or sodium hexanitrocobaltate(III). An 
acylation of the selected 1,3-diaryltriazenes 1 into N-acyl-1,3-diaryltriazenes 2–15 was achieved 
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by using the appropriate acyl chloride in the presence of triethylamine as a base. Acyl chlorides 
of nine different aliphatic, aromatic, and heteroaromatic carboxylic acids were selected, 
including acetyl, chloroacetyl, methoxyacetyl, acetoxyacetyl, benzoyl, fluorobenzoyl, 
(trifluoromethyl)benzoyl, pentafluorobenzoyl, nicotinoyl, and isonicotinoyl chlorides. In 
addition, four different triazenide salts were prepared from the diaryltriazene 1a. The reaction 
with methyl or ethyl propiolate in the presence of triethylamine afforded 
alkoxycarbonylvinyltriethylammonium salts 16a and 17a, whereas the trituration with 
triethylamine and potassium hydroxide gave triazenide salts 18a and 19a respectively (Scheme 
1). 
 
Antimicrobical properties 
Initial susceptibilities to compounds 1–19 were determined for M. smegmatis MC2 155, 
MRSA USA300 (as a representative of Gram-positive pathogen), E. coli DH10β, as a 
representative Gram-negative bacterium, and Sacharomyces cervisiae (S. cervisiae) wild strain 
as a representative eukaryote. The results are presented in Table 1. None of the examined 
compounds 1–19 however were found to be toxic towards S. cerevisiae.  
 
Table 1. The initial MIC (minimal inhibitory concentrations) and MBC (minimal bactericidal 
concentration) screenings of the compounds 1–19 
  M. smegmatis MC2 155 MRSA USA300 E. coli DH10 S. cerevisiae wild strain 
Compd MICa MBCa MICa MBCa MICa MBCa MICa MBCa 
1a >128 / >128 / >128 / >128 / 
1b / / >128 / / / >128 / 
1c >128 / >128 / >128 / >128 / 
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1d / / >128 / / / >128 / 
1e >128 / 2 4 >128 / >128 / 
1f >128 / >128 / >128 / >128 / 
1g 8 128 1 1 >128 / >128 / 
1h >128 / >128 / >128 / >128 / 
2a 16 128 0.25 0.25 64 >128 >128 / 
2e 16 >128 4 4 64 >128 >128 / 
2i 128 >128 8 32 32 128 >128 / 
2j >128 / >128 / 64 128 >128 / 
3a 32 >128 2 2 128 >128 >128 / 
3b / / >128 >128 / / >128 / 
3d / / >128 >128 / / >128 / 
3k >128 / >128 / 64 128 >128 / 
4e 128 >128 32 32 64 128 >128 / 
5k >128 / 8 16 64 64 >128 / 
6a 32 >128 0.5 0.5 >128 / >128 / 
6e 128 >128 32 32 32 32 >128 / 
7a >128 / >128 / 128 128 >128 / 
7e >128 / >128 / 64 128 >128 / 
7k >128 / >128 / 64 64 >128 / 
8e 32 >128 8 8 32 64 >128 / 
8k 128 >128 8 8 32 64 >128 / 
9e 16 >128 8 8 64 128 >128 / 
10a 16 128 0.25 0.5 >128 / >128 / 
10e >128 / >128 / 64 128 >128 / 
10k >128 / >128 / 128 128 >128 / 
11e >128 / 16 16 64 64 >128 / 
12k >128 / >128 / 64 64 >128 / 
13a 32 >128 2 2 128 >128 >128 / 
14e 64 128 32 32 32 32 >128 / 
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14i >128 / 64 64 128 >128 >128 / 
14j >128 / 64 128 8 16 >128 / 
14k 64 128 32 32 16 32 >128 / 
14l 64 >128 4 4 32 64 >128 / 
15e 128 >128 16 16 16 16 >128 / 
15i >128 / 32 32 >128 / >128 / 
15j >128 / 128 128 16 32 >128 / 
15k 128 >128 32 32 32 32 >128 / 
15l 64 >128 2 2 32 32 >128 / 
16a 4 16 0.0156 0.0156 >128 / >128 / 
17a 4 32 0.03125 0.03125 >128 / >128 / 
18a 0.03125 0.5 0.0156 0.03125 / / >128 / 
19a 0.03125 0.5 0.0156 0.0156 / / >128 / 
a In μg/mL.  
 
#R3#The most potent of the diaryltriazene compounds against MRSA USA300 that we 
identified (16a–19a inclusive which have MIC values of <0.02 μg/mL) compare favorably with 
reported susceptibilities for this organism: gentamycin 0.5–8 μg/mL, kanamycin >64 μg/mL, 
tobramycin 0.5–2 μg/mL, rifampin <0.125–0.5 μg/mL, ciprofloxacin 0.125–>64 μg/mL, 
levofloxacin 0.25–32 μg/mL, gatifloxacin 0.5–4 μg/mL, vancomycin 0.25–2 μg/mL, teichoplanin 
<0.125–0.25 μg/mL, clindamycin <0.125–>64 μg/mL, erythromycin 8–>64 μg/mL, linezolid 2–4 
μg/mL, oxacillin 16–32 μg/mL, chloroamphenicol 4–32 μg/mL, mupirocin 0.5–>64 μg/mL, 
fusidic acid <0.125–0.5 μg/mL, tetracycline <0.125–4 μg/mL, minocycline, and doxycycline 
both <0.125–0.5 μg/mL.18 
Similarly, the diaryltriazenes we identified with potent antibacterial activity against M. 
smegmatis again compare favorably in potency with established antibiotics which this organism 
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is resistant to. For example, MIC values for β-lactams (amoxicillin 8–16 μg/mL, ampicillin 128 
μg/mL, carbenicillin 512 μg/mL, oxacillin 32 μg/mL cefoxitin 2–4 μg/mL and ceftriaxone 32 
μg/mL)19 and also for vancomycin (45 μg/mL) and D-cycloserine (105 μg/mL)20 are 
considerably greater than the MICs for 18a and 19a. 
The structure-activity relationship (SAR) for compounds 1–19 was determined for MRSA 
USA300 strain. One can see that the MIC values, spanning from >128 μg/mL to 0.0156 μg/mL, 
are highly dependent on structure. Briefly, the comparison of antibacterial activities for 
compounds 2a–j, 3a and 3k, having different R2 groups (H, F, Cl, Br, CF3) while keeping R4 
(NO2) unchanged, reveals a decreasing trend in MIC values according to the R
2 group, so that H 
< Br < F < Cl < CF3 (Table 1, Figure 2A). A comparison of the MIC values for the compounds 
3a, 3b, and 3d, having a fixed CF3 group at R
2, indicates that the NO2 group at the position 4 of 
the 1,3-diphenyl rings is a crucial one, and substituting this group to Cl or CF3 deactivates the 
compound (Figure 2B). The above results suggest that the 4-nitro-2-(trifluoromethyl)phenyl 
pattern may be the key structural element in identifying the “hit” diaryltriazene compound (R2 = 
CF3, R
4 = NO2, Figure 2C), #R5#at least within the derivatives under this investigation that 
possess electron-deficient 1,3-diaryl substituents. 
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Figure 2. A) The general structure of diaryltriazenes with a variable group R2; B) The general 
structure of diaryltriazenes with a variable group R4; C) The structure of the parent fragment 
crucial for the antibacterial activity; D) The effect of “N1 substitution pattern” on antibacterial 
activity of 1,3-bis(4-nitro-2-(trifluoromethyl)phenyl)triazenes. 
 
Also evident from Table 1 is the influence of the N-acyl group in N-acyl-1,3-diaryltriazenes on 
MIC value. Higher activity is observed for the N-acyl groups that have a more electron deficient 
carbonyl group (for example, comparing MICs between 2a and 3a; Table 1, Figure 2D). The 
trend suggests that the liberation of a triazenide anion, presumably through the reaction of N-
acyl-1,3-diaryltriazenes with intracellular nucleophilic reagents, may play a role in the 
compounds antibacterial activity. This is in line with the triazenide salts 16–19 being the most 
potent killers of strain MRSA USA300. The selection of the cation in the triazenide salts 16–19 
appears not to be important in the activity against MRSA USA300, although this was not found 
for M. smegmatis (comparing 16a and 17a with 18a and 19a). 
Interestingly, some of the examined compounds, notably 14j, showed a significant activity 
against the wild type E. coli strain (Table 1). This observation, although not investigated further 
here, opens the possibility of discovering novel diaryltriazene derivatives, possessing greater 
potencies against Gram-negative organisms. This could be particularly important observation 
given the clinical concern currently associated with multi-drug resistant Gram-negative 
infections. 
As non-specific bactericidal activity usually corresponds to the lack of prokaryotic specificity 
and therefore potential toxicity in mammals,21 we decided to focus on identifying potentially 
membrane-damaging diaryltriazenes. 
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The BacLight™ assay is a particularly useful probe for determining the effect of compounds 
on bacterial membrane integrity.22 Ten of the most active diaryltriazenes (1g, 1e, 2a, 3a, 6a, 10a, 
16a, 17a, 18a, and 19a) having MICs against MRSA USA300 of less than 2 μg/mL, were 
selected for testing using this assay. The results of these assays on the cell membrane of this 
strain are summarized in Table 2. Here it can be seen that all the tested compounds, with the 
exception of compound 1, are potentially not membrane damaging. 
 
Table 2. MRSA USA300 membrane integrity 
  MRSA USA300 
Compd c (μg/mL) cells with intact membrane (%)a 
1e 8 64.6±9.4 
1g 2 31.2±3.2 
2a 2 103.0±5.8 
3a 8 100.0±2.4 
6a 2 95.8±2.3 
10a 2 103.8±4.7 
16a 2 105.5±1.3 
17a 2 107.3±3.5 
18a 2 104.3±6.5 
19a 2 107.6±9.6 
a The compounds upon which the amount of MRSA USA300 with intact membrane was 95% 
and 110% are not considered to be membrane damaging. Data are shown as mean±SD obtained 
from at least three independent experiments. 
 
Nine of the above compounds (1g, 2a, 3a, 6a, 10a, 16a, 17a, 18a, and 19a) were then selected 
for further evaluation of their antimicrobial activity against a variety of Gram-positive and 
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Gram-negative bacteria. The results are summarized in Table 3. #R8#All selected compounds 
are water soluble small molecules, stable in solid state as well as in solution of common organic 
solvents and water. As such, they could be relatively easily modified for further optimization.23  
 
Table 3. Susceptibility (MIC, MBC) of the selected diaryltriazenes to the different Gram-
positive and Gram-negative bacteria 
Organism 
 
Compd 
1g 2a 3a 6a 10a 16a 17a 18a 19a 
MRSA wild 
strain 1653 
MICa 1 0.25 0.03 0.5 0.5 0.0156 0.0156 0.0156 0.0156 
MBCa 1 0.5 0.5 1 4 0.25 0.25 0.25 0.5 
S. pneumoniae R6 
MICa 0.5 0.06 0.03125 0.5 0.5 0.0156 0.0156 0.0156 0.0156 
MBCa 1 0.5 0.125 1 1 0.125 0.125 0.125 0.125 
B. subtilis ATCC 
6051 
MICa 1 0.125 0.03125 0.5 2 0.0156 0.0156 
0.0312
5 
0.0312
5 
MBCa 32 4 4 16 >64 2 2 2 2 
Vancomycin 
resistant E. 
faecalis 501 
MICa 2 4 1 >128 >128 0.5 0.5 1 0.5 
MBCa >128 >128 >128 / / >128 >128 >128 >128 
P. aeruginosa 
PA0001 
MICa >128 >128 >128 >128 >128 >128 >128 >128 >128 
MBCa / / / / / / / / / 
P. aeruginosa 
ATCC 27853 
MICa / / >128 / / >128 >128 >128 >128 
MBCa / / / / / / / / / 
K. pneumoniae 
ATCC 13882 
MICa >128 >128 >128 >128 >128 >128 >128 >128 >128 
MBCa / / / / / / / / / 
K. pneumoniae 
ATCC 700603 
MICa >128 >128 >128 >128 >128 >128 >128 >128 >128 
MBCa / / / / / / / / / 
A. baumannii 
ATCC 19606 
MICa >128 >128 >128 >128 >128 >128 >128 >128 >128 
MBCa / / / / / / / / / 
A. baumannii 
MICa >128 >128 >128 >128 >128 >128 >128 >128 >128 
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BAA1605 MBCa / / / / / / / / / 
a In μg/mL. 
 
We were unable to detect activity of the selected compounds in Gram-negative strains, i.e. E. 
coli (Table 1), P. aeruginosa, K. pneumonia, A. baumannii (Table 3). This may have been due to 
a lack of penetration of the tested compounds through the outer membranes of these organisms, 
or possibly due to efficient efflux functioning. To decipher between these two possibilities we 
performed MIC evaluations of the selected compounds using an E. coli membrane permeable 
strain of D22 and an E. coli strain of D22 with knockout of the membrane pump N43 CGSC 
5583. The results, presented in Table 4, suggest that the inactivity of the tested compounds in the 
case of Gram negative-bacteria, represented by the E. coli DH10β strain, was indeed related to 
low permeability of the Gram-negative outer membrane to these compounds. #R1# Aberrant 
behaviour of compounds 6a and 10a could arise from their structure. These compounds are 
unique amongst those tested from Table 3, by their possession of (substituted) N-benzoyl group. 
Although this may well be an issue that uniquely impinges upon the ability of 6a and 10a to 
penetrate cells, the explanation of the actions of 6a and 10a may also reside with the E. coli 
strain D22 used in these experiments. D22 contains a mutation in the LpxC gene which encodes 
UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase, an enzyme involved in 
the synthesis of lipid A.24,25 Lipid A is a lipopolysaccharide appended to the outer membrane of 
E. coli. Perturbations to its synthesis caused by LpxC mutations would likely impact upon the 
ability of hydrophobic compounds such as 6a and 10a to penetrate the cell. 
 
Table 4. MIC and MBC evaluation for E. coli membrane permeable strain D22, and an E. coli 
strain containing a knockout of the membrane pump N43 CGSC 5583 
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Compd 
E. coli membrane 
permeable strain 
D22 
E. coli knockout of 
membrane pump N43 CGSC 
5583 
MICa MBCa MICa MBCa 
1g 2 >128 >128 / 
2a 1 >128 >128 / 
3a 0.5 16 >128 / 
6a >128 / >128 / 
10a >128 / >128 / 
16a 0.25 >128 >128 / 
17a 0.5 >128 >128 / 
18a 0.5 >128 >128 / 
19a 0.5 >128 >128 / 
a in μg/mL. 
 
#R9#Critically, resistance to methicillin and vancomycin underpins medically intractable 
infections caused by MRSA and vancomycin resistant enterococci (VRE). The acute 
diaryltriazene sensitivity of MRSA USA300, a highly resistant clinical MRSA strain, therefore 
prompted us to investigate the possibility that our antimicrobial diaryltriazene compounds might 
sensitise these pathogens to -lactams and vancomycin, which would ultimately be of clinical 
interest. However, no synergism26 between the compound 16a, one of the most promising new 
diaryltriazene compounds, was detected when tested with methicillin against MRSA, nor with 
vancomycin against Vancomycin resistant E. faecalis (VRE). This finding led us to conclude that 
the mode of action of the diaryltriazene 16a was either unrelated to the action of methicillin and 
vancomycin (bacterial peptidoglycan biosynthesis) or did not impact on the resistance 
mechanisms employed by MRSA and VRE towards -lactams and glycopeptides. 
In order to better characterise the mode of action of the compound 16a, MRSA strain USA300 
was grown continuously in the presence of this active compound, at progressively inhibitory 
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concentrations (2-, 4-, 6- and 8-times it’s MIC value), allowing resistance to develop. Following 
incubation three 16a-resistant MRSA USA300 isolates were obtained. In addition the mutation 
rate of the MRSA USA300 strain when exposed to the different concentrations of the compound 
16a was also determined. #R2#We have also obtained MICs values of all three resistant isolates 
(Table 5). 
 
Table 5. Mutation rate assaya and resistant strains isolated  
Diaryltriazene 16a 
16a-resistant 
isolate name Concentration 
(μg/mL) 
Mutation rate MIC (μg/mL) 
0.03125 3.9610–6 0.03125 Isolate R1 
0.0625 810–9 0.03125 Isolate R2 
0.09375 810–9 0.0625 Isolate R3 
0.125 < 810–9 / / 
a Mutation rate assays were performed using MRSA USA300 strain. 
 
MRSA USA300 isolates resistant to the compound 16a, and sensitive parental strains were 
subjected to whole genome sequencing in order to identify the underlying genetic 
polymorphisms present in resistant isolates. Resistant isolates (identified as Isolates R1, R2, and 
R3) were compared to the parental (control) strain, allowing the genetic polymorphisms 
differentiating these isolates to be identified (Figure 3). 
Isolate R1 contained a single 48 base pair deletion at the position 128454 of the genome, 
corresponding to the position of a pseudogene in the reference, which appeared to be reactivated 
by this deletion. The gene was identified as Staphylococcal protein A (SpA), a known virulence 
protein. The deletion occurred at amino acid (AA) position 390 of the 522AA protein, causing 
 16 
the protein to shift back into frame. A comparison with the NCBI blast database revealed that 
this was a common deletion found among S. aureus isolates. Cell wall associated SpA functions 
to bind the Fc domain of human immunoglobulin.27 This molecule consists of a hydrophobic C-
terminal, thought to be embedded within the cell membrane, flanked at the N-terminal end by a 
charged tail.28,29 The mechanism by which this protein reduces its sensitivity to the diaryltriazene 
16a therefore remains unclear; its surface location could however affect the interaction or 
permeability of the cell to this compound. 
Isolate R2 carried a single non-synonymous single nucleotide polymorphism (SNP) at position 
1396319 when compared to the control strain. This guanine to thymine SNP altered the amino 
acid sequence of fmtC, a lysylphosphatidylglycerol synthetase, an 843 amino acid protein, from 
Glu307, to an ATG “stop” codon. This gene is not essential in S. aureus. The function of FmtC 
appears to be to impart a positive charge on the negatively charged phospholipid membrane 
bilayer.30 This is achieved through the addition of a lysine residue, through the positive charge of 
its epsilon amino group. This altering of the surface charge as a route to antibiotic resistance is 
widely documented, particularly for the pore-forming peptides such as nisin.31,32 Quenching of 
the membranes negative charge through the lysine addition is therefore likely to reduce a 
repulsion of the negatively charged diaryltriazenes, facilitating their penetration. A loss of FmtC 
function or efficacy could therefore affect the interaction between negatively charged 
diaryltriazene and the negatively charged membrane leading to resistance. 
Isolate R3 carried two mutations relative to the control, a non-synonymous SNP at position 
2496871, and a single thymine insertion at position 2496195, in an intergenic region. The 
guanine to thymine SNP resulted in an arginine to leucine substitution at the AA-position 197 of 
the 210 AA DNA-binding helix-turn-helix (HTH) domain of a possible transcriptional regulator. 
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Using the Basic Local Alignment Search Tool (BLAST) this gene most closely resembled a 
Tetracycline Repressor (TetR) family transcriptional regulator- so named owing to their 
involvement with tetracycline resistance in S. aureus.33  
The thymine insertion at position 2496195 occurred in an intergenic region prior to the 
possible transcriptional regulator described above, on the forward strand, and upstream from a 
hypothetical membrane protein on the reverse strand. Using the prediction software PEPPER34 
this region was predicted to contain a promoter sequences in the forward direction.33 This 
suggested that expression levels for the predicted transcriptional regulator could have been 
affected. However, it remains unclear as to how mutations in a gene associated with tetracycline 
resistance impact upon diaryltriazene resistance. 
Therefore, no single target could be identified for the activity of the compound 16a. Instead, 
changes in MIC appear to have resulted from independent mechanisms unique to each mutant 
isolate. 
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Figure 3. Mutant isolates of MRSA USA300 compared to the control. The figure illustrates the 
genomic locations of the different mutations relative to the control. The outer scale bar indicates 
the number of base pairs from the replication origin, and can be used to compare the approximate 
genomic locations for each of the mutations identified. 
 
To assess the specificity and translational benefit that might arise from antimicrobials based 
upon the diaryltriazene compounds used in this research we assessed the impact of the most 
promising triazenide salt 16a, as well as 17a, 18a, and 19a on human keratinocytes. The results 
(Figure 4) show that keratinocytes survived significantly higher concentrations of triazenide salts 
compared to those concentrations which inhibited the growth of MRSA USA300, M. smegmatis 
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(Table 1), MRSA wild strain, S. pneumoniae, Bacillus subtilis or Vancomycin resistant E. 
faecalis (Table 3). This data clearly indicates a marked selectivity of these diaryltriazenes 
towards bacterial growth inhibition. 
 
 
Figure 4. Survival of healthy human keratinocytes treated with compounds 16a, 17a, 18a and 
19a. 
 
#R7# The SAR conducted suggested a strong role for the nitro group on the antibacterial 
efficacy. Although nitroarenes are less preferred scaffolds in drug discovery due to their potential 
mutagenicity, certain drugs do contain this moiety.35 These include chloramphenicol and 
metronidazole, which are on the WHO Model List of Essential Medicines.36 Despite the potential 
threat, recent endeavor of the group of Panda has shown promise in mitigating the mutagenic 
nature of nitroarenes.37  
It is interesting to note that the structures of 1,3-diaryl substituents at the triazenes identified in 
this work has a similarity with benzothiazinones (BTZ043) and related compounds.14,35,38 For 
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antitubercular activity, it was found that these compounds need to be functionalized with nitro 
group as well as a meta- electron-withdrawing group, typically either a trifluoromethyl or 
another nitro. The nitroaromatic group was postulated to undergo bioreduction to a 
corresponding nitrosoarene which then reacts with an active site cysteine residue in the DprE1 
enzyme to form a semimercaptal adduct inactivating the enzyme.14,35,38 Recent chemical studies 
on BTZ043 confirmed the postulated reactivity, indicating that thiolates and other nucleophiles 
induce nonenzymatic reduction of the nitro groups to the corresponding nitroso intermediates.39 
We conducted NMR experiment where equimolar amounts of reduced glutathione (GSH) and 
triazenide salt 19a were incubated at room temperature in a mixture of DMSO-d6 and phosphate 
buffer of pH 7.4 (1:1, v/v). The reaction mixture was monitored by 1H NMR spectroscopy for 24 
h indicating no changes in the aromatic region of the spectra. This suggests that the molecular 
mechanism of action of 1,3-diarlytriazenes under this investigation may be different to that of 
BTZ043.  
The biological activity of alkyltriazenes has been associated to degradation products involved, 
forming reactive diazonium species.11,12 In contrast, compounds 1a and 19a were found to be 
stable in phosphate buffer solutions at pH 7.4 with no detectable decomposition as indicated by 
TLC and NMR analyses. Thus, the molecular mechanism of antibacterial activity of 1,3-
diaryltriazenes is yet to be explored, and will be the subject of forthcoming investigations.  
 
CONCLUSIONS 
Here we have described the synthesis of a library of 1,3-diaryltriazenes, their N-acyl 
derivatives, and their salts. The structure-activity relationships (SAR) of these compounds 
revealed that the antimicrobial properties of these compounds depended on the type of 
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substituent group attached to the two constituent benzene rings. Specifically, a trifluoromethyl 
group at position 2, and a nitro substituent at position 4 of the triazene were found to be critical 
to its activity. 
Regarding the biological activities of the new compounds, the most important result from our 
study was that the selected compounds 16a, 17a, 18a and 19a were extremely active against one 
of the most clinically important bacterial species, MRSA. These compounds were not found to 
be membrane damaging to MRSA USA300. The molecular basis of the triazene activity against 
S. aureus remained unclear, with the appearing to more than one mechanism of killing based on 
the observed mutations identified among resistant isolates. Where a mechanism could be 
characterized, it appeared that changes in the phospholipid composition of the staphylococcal 
cell membrane were ultimately responsible. In addition, the selected compounds were found to 
be very effective against other Gram-positive bacteria, such as S. pneumoniae, B. subtilis, 
Vancomycin resistant E. faecalis, and M. smegmatis. Promising activities of a number of the 
triazene family compounds towards E. coli were also found. The majority of the tested 
compounds were however inactive against Gram-negative organisms, with membrane 
penetration found to be limiting in E. coli. 
These compounds were also found to be inactive against lower eukaryotes (yeast), and more 
importantly, exhibited only a low cytotoxicity against human keratinocytes (as compared to the 
cytotoxicity observed towards certain pathogenic bacteria). These characteristics are promising 
with respect to the potential clinical utility of these triazenes for use as novel antimicrobials. Our 
data suggest that 1,3-diaryltriazenes could represent a new class of antibacterial drug. 
 
EXPERIMENTAL SECTION 
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Chemistry. Starting materials and solvents for the synthesis of the examined compounds were 
used as obtained, and without further purification, from Aldrich, Fluka, Alfa Aesar and 
Maybridge Chemical Company Ltd). Melting points were determined on a Kofler micro hot 
stage and were uncorrected. NMR spectra were recorded with a Bruker Avance III 500 MHz 
instrument operating at 500 MHz (1H), 126 MHz (13C) at 296 K. Proton spectra were referenced 
to Si(CH3)4 as the internal standard (δ = 0.00 ppm) and carbon chemical shifts were given against 
the central line of the solvent signal (CDCl3 at δ = 77.0 ppm). Chemical shifts were given on the 
δ scale (parts per million) and coupling constants (J) were given in Hertz. IR spectra were 
obtained with a Bruker ALPHA Platinum ATR spectrometer on a solid sample support (ATR). 
High-resolution mass spectrometry (HRMS) analysis was performed using an Agilent 6224 
Accurate Mass TOF LC/MS spectrometer. Elemental analyses (C, H, N) were performed with 
Perkin Elmer 2400 Series II CHNS/O Analyser. The progress of all reactions was monitored on 
Fluka silica-gel TLC-plates (with fluorescence indicator UV254), using ethyl acetate/petroleum 
ether as the solvent system. A column chromatography was performed using Merck silica gel 60 
(35−70 μm) with solvent mixtures as specified in the corresponding experiments. All the 
compounds tested were of 95% purity, as verified by 1H NMR and 13C NMR spectroscopy as 
well as with elemental microanalysis. The values obtained for C, H, N analyses were within 
0.40% of the calculated values. 
Materials. The compounds 1a, 1c–1h, 2, 3a, 4–13 and 18 were prepared according to known 
procedures.15,16,40 Precursor 1,3-diaryltriazenes, i.e., 1,3-bis(2-fluoro-4-nitrophenyl)triazene, 1,3-
bis(2-methyl-4-nitrophenyl)triazene, 1,3-bis(2-bromo-4-nitrophenyl)triazene, and 1,3-bis(4-
nitro-3-(trifluoromethyl)phenyl)triazene, that were used for the acylation shown in Scheme 1 into 
2i, 2j, 3k, 5k, 7k, 8k, 10k, 12k, 14i–l, 15i–l, were synthesized as described in the literature.6 
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Preparation of 1,3-bis(2,4-bis(trifluoromethyl)phenyl)triazene (1b). An aqueous solution 
of sodium nitrite (0.035 g, 0.5 mmol/10 mL) was added dropwise to the solution of 2,4-
bis(trifluoromethyl)aniline (0.229 g, 1 mmol) in 5% aqueous HCl (2.5 mL) at 0 °C. The reaction 
mixture was stirred at room temperature for 20 h. Then, the solid material was filtered and 
washed with water. 
Pale yellow solid; yield 75%, mp 91–93 °C (MeOH/H2O); IR: 3343, 3101, 1632, 1594, 1527, 
1487, 1455, 1426, 1347, 1306 cm–1; 1H NMR (500 MHz, DMSO-d6): δ (ppm) 7.89–7.95 (m, 
2H), 8.08–8.18 (m, 4H), 13.25 (s, 1H); HRMS (ESI+) m/z for C16H8F12N3+ [M + H]+: calcd 
470.0521, found 470.0517. Anal. calcd for C16H7F12N3: C, 40.95; H, 1.50; N, 8.96; found C, 
41.02; H, 1.37; N, 9.08. 
 
General procedures for the synthesis of 3-acyl-1,3-diaryltriazenes 2–15 
Method A. (3b, 3d, 3k) Triethylamine (0.279 mL, 2 mmol) was added to a stirred suspension 
of the appropriate triazene 1 (1 mmol) in acetonitrile (10 mL) at room temperature, followed by 
the addition of chloroacetyl chloride (0.155 mL, 2 mmol). After additional stirring for 10 min, 
the reaction mixture was evaporated to dryness under reduced pressure. Then, water (5 mL) was 
added and the water phase was washed with dichloromethane (3 × 10 mL). Combined organic 
phases were first washed with water (20 mL) and then dried over anhydrous Na2SO4, filtered and 
evaporated under reduced pressure to dryness yielding the crude products 3. Thereafter, products 
were recrystallized using the appropriate solvents. 
 
Method B. (14, 15) Triethylamine (0.558 mL, 4 mmol) was added to a stirred suspension of the 
appropriate triazene 1 (1 mmol) in dry acetonitrile (20 mL) at room temperature, followed by the 
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addition of nicotinoyl chloride (isonicotinoyl chloride in cases of 15). After additional stirring for 
10–20 min, the reaction mixture was evaporated to dryness under reduced pressure, treated with 
methanol, filtered off and washed with saturated NaHCO3 solution and methanol yielding the 
crude products 14 and 15. Thereafter, all products were recrystallized using the appropriate 
solvents. 
 
General procedures for the synthesis of triazenide salts 16–19 
Method C. (16, 17) Triethylamine (0.558 mL, 4 mmol) was added to a stirred suspension of 
1,3-bis(4-nitro-2-(trifluoromethyl)phenyl)triazene (1a) (0.424 g, 0.5 mmol) in acetonitrile (7 mL) 
at room temperature followed by the addition of methyl propiolate (ethyl propiolate in the case 
of 17a). After additional stirring for 1 h, the reaction mixture was evaporated to dryness under 
reduced pressure, treated with diethyl ether and filtered off, yielding the crude products 16a and 
17a. Thereafter, both products were recrystallized using the appropriate solvents. 
 
Method D. (19) A solution of KOH (0.224 g, 4 mmol) in water (20 mL) was added to a stirred 
solution of 1,3-bis(4-nitro-2-(trifluoromethyl)phenyl)triazene in acetonitrile (10 mL) at room 
temperature. After additional stirring for 20 min, acetonitrile was evaporated under reduced 
pressure, and the precipitate was filtered off, yielding 19a. A crude product was recrystallized 
from acetonitrile/water mixture. 
1-(1,3-Bis(2,4-bis(trifluoromethyl)phenyl)triaz-2-en-1-yl)-2-chloroethanone (3b). Method 
A. Pale yellow solid; yield 91%; mp 85–87 °C (petroleum ether); IR: 1744, 1626, 1596, 1492, 
1345, 1304, 1274, 1232, 1160, 1120 cm–1; 1H NMR (500 MHz, CDCl3): δ (ppm) 4.73–4.90 (m, 
2H), 7.35–7.42 (m, 1H), 7.71–7.77 (m, 1H), 7.88–7.98 (m, 2H), 7.98–8.03 (m, 1H), 8.07–8.12 
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(m, 1H); 13C NMR (126 MHz, CDCl3): δ (ppm) 41.7, 118.7, 121.9 (q, J = 273 Hz), 122.2 (q, J = 
273 Hz), 122.8 (q, J = 273 Hz), 122.9 (q, J = 273 Hz), 124.3–124.5 (m), 124.8–125.0 (m), 127.6 
(q, J = 32 Hz), 130.0 (q, J = 32 Hz), 131.9 (q, J = 32 Hz), 132.2, 133.2 (q, J = 32 Hz), 136.1, 
147.1, 167.8; HRMS (ESI–) m/z for C16H6F12N3– [M – COCH2Cl]–: calcd 468.0376, found 
468.0380. Anal. calcd for C18H8ClF12N3O: C, 39.62; H, 1.48; N, 7.70; found: C, 39.76; H, 1.43; 
N, 7.60. 
1-(1,3-Bis(4-chloro-2-(trifluoromethyl)phenyl)triaz-2-en-1-yl)-2-chloroethanone (3d). 
Method A. Yellow solid; yield 96%; mp 83–85 °C (diisopropyl ether); IR: 3109, 3015, 2960, 
2122, 1733, 1714, 1599, 1501, 1481, 1413 cm–1; 1H NMR (500 MHz, CDCl3): δ (ppm) 4.74 (d, J 
= 13.9 Hz, 1H), 4.82 (d, J = 13.9 Hz, 1H), 7.11–7.16 (m, 1H), 7.57–7.63 (m, 2H), 7.65–7.71 (m, 
2H), 7.79–7.83 (m, 1H); 13C NMR (126 MHz, CDCl3): δ (ppm) 41.9, 119.1, 121.8 (q, J = 274 
Hz), 122.2 (q, J = 274 Hz), 127.2 (q, J = 5 Hz), 127.9 (q, J = 5 Hz), 128.6 (q, J = 32 Hz), 130.4 
(q, J = 32 Hz), 131.2 (q, J = 2 Hz), 132.6, 132.8, 133.2, 136.1, 136.8, 143.1, 167.8; HRMS 
(ESI–) m/z for C14H6Cl2F6N3– [M – COCH2Cl]–: calcd 399.9848, found 399.9852. Anal. calcd 
for C16H8Cl3F6N3O: C, 40.15; H, 1.68; N, 8.78; found: C, 39.91; H, 1.60; N, 8.57. 
1-(1,3-Bis(2-bromo-4-nitrophenyl)triaz-2-en-1-yl)-2-chloroetanone (3k). Method A. 
Yellow solid; yield 91%; mp 151–153 °C (dichloromethane/diisopropyl ether); IR: 3101, 3076, 
3002, 2958, 2112, 1991, 1922, 1720, 1594, 1580 cm–1; 1H NMR (500 MHz, CDCl3): δ (ppm) 
4.76–4.90 (m, 2H), 7.44–7.49 (m, 1H), 7.59–7.65 (m, 1H), 8.23–8.29 (m, 1H), 8.33–8.38 (m, 
1H), 8.50–8.54 (m, 1H), 8.60–8.65 (m, 1H); 13C NMR (126 MHz, CDCl3): δ (ppm) 41.8, 119.8, 
122.3, 123.5, 123.5, 124.1, 128.7, 129.2, 131.6, 140.4, 148.2, 148.9, 149.8, 167.2; HRMS (ESI–) 
m/z for C12H6Br2N5O4
– [M – COCH2Cl]–: calcd 441.8792, found 441.8792. Anal. calcd for 
C14H8Br2ClN5O5: C, 32.24; H, 1.55; N, 13.43; found: C, 32.31; H, 1.46; N, 13.32. 
 26 
(1,3-Bis(2-chloro-4-nitrophenyl)triaz-2-en-1-yl)(pyridin-3-yl)methanone (14e). Method B, 
reaction time: 20 min. Pale yellow solid; yield 66%; mp 128–132 °C (MeOH/acetone); IR: 3098, 
1703, 1584, 1528, 1474, 1351, 1226, 1144, 1134, 1120, 1047 cm–1; 1H NMR (500 MHz, CDCl3): 
δ (ppm) 7.36–7.43 (m, 1H), 7.50–7.56 (m, 1H), 7.58–7.65 (m, 1H), 8.07–8.13 (m, 1H), 8.19–
8.25 (m, 1H), 8.29–8.34 (m, 1H), 8.34–8.38 (m, 1H), 8.48–8.53 (m, 1H), 8.84–8.89 (m, 1H), 
9.10–9.16 (m, 1H); 13C NMR (126 MHz, CDCl3): δ (ppm) 119.7, 122.8, 122.9, 123.3, 125.6, 
126.2, 128.9, 131.8, 133.2, 134.4, 137.6, 139.1, 148.1, 148.5, 149.0, 150.7, 153.0, 168.6; HRMS 
for C18H11Cl2N6O5 [M + H]
+: calcd 461.0162, found 461.0164. Anal. calcd for C18H10Cl2N6O5 × 
0.5 H2O: C, 46.56; H, 2.53; N, 17.61; found: C, 46.41; H, 2.70; N, 17.78. 
(1,3-Bis(2-fluoro-4-nitrophenyl)triaz-2-en-1-yl)(pyridin-3-yl)methanone (14i). Method B, 
reaction time: 10 min. Brown solid; yield 76%; mp 126–128 °C (MeOH); IR: 3091, 1699, 1586, 
1526, 1483, 1417, 1346, 1308, 1261, 1241, 1216 cm–1; 1H NMR (500 MHz, CDCl3): δ (ppm) 
7.42–7.48 (m, 1H), 7.50–7.55 (m, 1H), 7.59–7.64 (m, 1H), 8.00–8.07 (m, 2H), 8.16–8.22 (m, 
2H), 8.24–8.30 (m, 1H), 8.83–8.88 (m, 1H), 9.09–9.13 (m, 1H); 13C NMR (126 MHz, CDCl3): δ 
(ppm) 112.7 (d, J = 25 Hz), 113.4 (d, J = 25 Hz), 120.0 (d, J = 15 Hz), 120.0 (d, J = 15 Hz), 
121.5, 123.3, 128.5 (d, J = 15 Hz), 128.8, 131.5, 137.8, 140.1 (d, J = 8 Hz), 148.5 (d, J = 8 Hz), 
149.6 (d, J = 8 Hz), 150.8, 153.0, 156.5 (d, J = 260 Hz), 157.4 (d, J = 260 Hz), 168.5; HRMS 
(ESI+) m/z for C18H11F2N6O5
+ [M + H]+: calcd 429.0754, found 429.0747. Anal. calcd for 
C18H10F2N6O5: C, 50.48; H, 2.35; N, 19.62; found: C, 50.30; H, 2.22; N, 19.42. 
(1,3-Bis(4-nitrophenyl)triaz-2-en-1-yl)(pyridin-3-yl)methanone (14j). Method B, reaction 
time: 10 min. Pale violet solid; yield 58%; mp 225–227 °C (MeOH); IR: 3054, 1689, 1610, 
1584, 1519, 1470, 1416, 1330, 1300, 1209, 1170, 1132 cm–1; 1H NMR (500 MHz, CDCl3): δ 
(ppm) 7.47–7.56 (m, 5H), 8.16–8.21 (m, 1H), 8.22–8.28 (m, 2H), 8.43–8.49 (m, 2H), 8.83–8.88 
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(m, 1H), 9.07–9.11 (m, 1H); 13C NMR (126 MHz, CDCl3): δ (ppm) 123.2, 123.3, 124.9, 125.0, 
129.5, 130.3, 137.7, 140.6, 148.2, 148.3, 150.8, 151.6, 152.8, 169.2; HRMS (ESI+) m/z for 
C18H13N6O5
+ [M + H]+: calcd 393.0942, found 393.0939. Anal. calcd for C18H12N6O5: C, 55.11; 
H, 3.08; N, 21.42; found: C, 54.86; H, 2.85; N, 21.33. 
(1,3-Bis(2-bromo-4-nitrophenyl)triaz-2-en-1-yl)(pyridin-3-yl)methanone (14k). Method B, 
reaction time: 20 min. Yellow-brown solid; yield 49%; mp 142–144 °C (MeOH/acetone); IR: 
3098, 1702, 1583, 1531, 1519, 1485, 1469, 1418, 1345, 1289, 1250, 1223 cm–1; 1H NMR (500 
MHz, CDCl3): δ (ppm) 7.33–7.39 (m, 1H), 7.50–7.55 (m, 1H), 7.57–7.61 (m, 1H), 8.13–8.18 (m, 
1H), 8.19–8.25 (m, 1H), 8.38–8.43 (m, 1H), 8.48–8.51 (m, 1H), 8.65–8.69 (m, 1H), 8.83–8.88 
(m, 1H), 9.12–9.16 (m, 1H); 13C NMR (126 MHz, CDCl3): δ (ppm) 119.5, 122.7, 123.3, 123.5, 
123.5, 124.0, 128.7, 129.0, 129.2, 131.8, 137.7, 141.1, 148.1, 148.8, 149.6, 150.7, 153.0, 168.1; 
HRMS (ESI+) m/z for C18H11Br2N6O5
+ [M + H]+: calcd 548.9152, found 548.9147. Anal. calcd 
for C18H10Br2N6O5: C, 39.30; H, 1.83; N, 15.28; found: C, 39.22; H, 1.73; N, 15.22. 
(1,3-Bis(4-nitro-3-(trifluoromethyl)phenyl)triaz-2-en-1-yl)(pyridin-3-yl)methanone (14l). 
Method B, reaction time: 10 min. Pale yellow solid; yield 36%; mp 131–133 °C (MeOH); IR: 
3094, 2018, 1698, 1587, 1538, 1495, 1477, 1419, 1354, 1314, 1293, 1271 cm–1; 1H NMR (500 
MHz, CDCl3): δ (ppm) 7.52–7.58 (m, 1H), 7.65–7.72 (m, 2H), 7.75–7.80 (m, 1H), 7.81–7.85 (m, 
1H), 7.92–7.98 (m, 1H), 8.11–8.16 (m, 1H), 8.17–8.22 (m, 1H), 8.85–8.92 (m, 1H), 9.08–9.13 
(m, 1H); 13C NMR (126 MHz, CDCl3): δ (ppm) 121.30 (q, J = 274 Hz), 121.33 (q, J = 274 Hz), 
123.0 (q, J = 5 Hz), 123.3, 125.21 (q, J = 35 Hz), 125.25 (q, J = 35 Hz), 125.6, 126.6, 126.8, 
128.8, 129.1 (q, J = 5 Hz), 134.1, 137.7, 138.4, 147.9, 148.3, 149.6, 150.7, 153.2, 168.89; HRMS 
(ESI+) m/z for C20H11F6N6O5
+ [M + H]+: calcd 529.0690, found 529.0690. Anal. calcd for 
C20H10F6N6O5: C, 45.47; H, 1.91; N, 15.91; found: C, 45.39; H, 1.91; N, 15.67. 
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(1,3-Bis(2-chloro-4-nitrophenyl)triaz-2-en-1-yl)(pyridin-4-yl)methanone (15e). Method B, 
reaction time: 20 min. Pale violet solid; yield 63%; mp 140–142 °C (MeOH/acetone); IR: 3092, 
1698, 1586, 1520, 1480, 1410, 1346, 1293, 1249, 1223, 1131 cm–1; 1H NMR (500 MHz, CDCl3): 
δ (ppm) 7.28–7.33 (m, 1H), 7.59–7.63 (m, 1H), 7.68–7.72 (m, 2H), 8.08–8.14 (m, 1H), 8.30–
8.34 (m, 1H), 8.34–8.39 (m, 1H), 8.49–8.54 (m, 1H), 8.85–8.93 (m, 2H); 13C NMR (126 MHz, 
CDCl3): δ (ppm) 119.6, 122.8, 123.0, 123.0, 125.7, 126.3, 131.7, 133.3, 134.4, 138.7, 140.4, 
148.2, 148.3, 149.1, 150.3, 168.6; HRMS for C18H11Cl2N6O5 [M + H]
+: calcd 461.0162, found 
461.0165. Anal. calcd for C18H10Cl2N6O5: C, 46.87; H, 2.19; N, 18.22; found: C, 46.76; H, 2.16; 
N, 18.01. 
(1,3-Bis(2-fluoro-4-nitrophenyl)triaz-2-en-1-yl)(pyridin-4-yl)methanone (15i). Method B, 
reaction time: 10 min. Brown solid; yield 57%; mp 136–138 °C (MeOH); IR: 3087, 1720, 1704, 
1592, 1531, 1482, 1405, 1349, 1310, 1262, 1243 cm–1; 1H NMR (500 MHz, CDCl3): δ (ppm) 
7.35–7.42 (m, 1H), 7.57–7.65 (m, 1H), 7.65–7.72 (m, 2H), 7.98–8.10 (m, 2H), 8.16–8.23 (m, 
1H), 8.24–8.32 (m, 1H), 8.79–8.99 (m, 2H); 13C NMR (126 MHz, CDCl3): δ (ppm) 112.7 (d, J = 
25 Hz), 113.4 (d, J = 25 Hz), 120.0 (d, J = 22 Hz), 120.0 (d, J = 22 Hz), 121.4, 123.1, 128.1 (d, 
J = 15 Hz), 131.5, 139.9 (d, J = 8 Hz), 140.2, 148.6 (d, J = 8 Hz), 149.7 (d, J = 8 Hz), 150.2, 
156.5 (d, J = 260 Hz), 157.3 (d, J = 260 Hz), 168.8; HRMS (ESI+) m/z for C18H11F2N6O5
+ [M + 
H]+: calcd 429.0754, found 429.0750. Anal. calcd for C18H10F2N6O5: C, 50.48; H, 2.35; N, 
19.62; found: C, 50.18; H, 2.22; N, 19.36. 
(1,3-Bis(4-nitrophenyl)triaz-2-en-1-yl)(pyridin-4-yl)methanone (15j). Method B, reaction 
time: 10 min. Yellow solid; yield 94%; mp 156–158 °C (MeOH/acetone); IR: 3034, 1699, 1609, 
1591, 1553, 1518, 1489, 1476, 1407, 1366, 1343, 1295 cm–1; 1H NMR (500 MHz, CDCl3): δ 
(ppm) 7.42–7.54 (m, 4H), 7.63–7.70 (m, 2H), 8.21–8.28 (m, 2H), 8.43–8.49 (m, 2H), 8.85–8.91 
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(m, 2H); 13C NMR (126 MHz, CDCl3): δ (ppm) 100.0, 123.1, 123.2, 124.9, 125.0, 130.2, 140.2, 
141.0, 148.3, 150.2, 151.4; HRMS (ESI+) m/z for C18H13N6O5
+ [M + H]+: calcd 393.0942, found 
393.0944. Anal. calcd for C18H12N6O5: C, 55.11; H, 3.08; N, 21.42; found: C, 54.86; H, 2.88; N, 
21.45. 
(1,3-Bis(2-bromo-4-nitrophenyl)triaz-2-en-1-yl)(pyridin-4-yl)methanone (15k). Method B, 
reaction time: 20 min. Pale yellow solid; yield 67%; mp 162–164 °C (MeOH/acetone); IR: 3087, 
2112, 1698, 1593, 1521, 1480, 1409, 1344, 1290, 1249, 1211 cm–1; 1H NMR (500 MHz, CDCl3): 
δ (ppm) 7.26–7.31 (m, 1H), 7.57–7.61 (m, 1H), 7.69–7.74 (m, 2H), 8.12–8.18 (m, 1H), 8.39–
8.43 (m, 1H), 8.48–8.52 (m, 1H), 8.66–8.70 (m, 1H), 8.86–8.90 (m, 2H); 13C NMR (126 MHz, 
CDCl3): δ (ppm) 119.4, 122.8, 123.0, 123.5, 123.6, 124.0, 128.7, 129.2, 131.8, 140.4, 140.7, 
148.2, 148.9, 149.5, 150.3, 168.4; HRMS (ESI+) m/z for C18H11Br2N6O5
+ [M + H]+: calcd 
548.9152, found 548.9149. Anal. calcd for C18H10Br2N6O5: C, 39.30; H, 1.83; N, 15.28; found: 
C, 39.31; H, 1.74; N, 15.18. 
(1,3-Bis(4-nitro-3-(trifluoromethyl)phenyl)triaz-2-en-1-yl)(pyridin-4-yl)methanone (15l). 
Method B, reaction time: 10 min. Pale yellow solid; yield 72%; mp 128–130 °C 
(MeOH/acetone); IR: 3079, 1704, 1594, 1535, 1476, 1415, 1354, 1294, 1271, 1210, 1135 cm–1; 
1H NMR (500 MHz, CDCl3): δ (ppm) 7.61–7.71 (m, 4H), 7.75–7.79 (m, 1H), 7.80–7.83 (m, 1H), 
7.92–7.97 (m, 1H), 8.11–8.16 (m, 1H), 8.87–8.93 (m, 2H); 13C NMR (126 MHz, CDCl3): δ 
(ppm) 121.3 (q, J = 274 Hz), 121.3 (q, J = 274 Hz), 122.9 (q, J = 5 Hz), 123.1, 125.3 (q, J = 35 
Hz), 125.5 (q, J = 35 Hz), 125.7, 126.6, 126.8, 129.0 (q, J = 5 Hz), 134.0, 138.0, 140.2, 148.1, 
148.4, 149.5, 150.3, 169.2; HRMS (ESI+) m/z for C20H11F6N6O5
+ [M + H]+: calcd 529.0690, 
found 529.0688. Anal. calcd for C20H10F6N6O5: C, 45.47; H, 1.91; N, 15.91. Found: C, 45.25; H, 
1.76; N, 15.63. 
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N,N,N-triethyl-3-methoxy-3-oxoprop-1-en-1-aminium 1,3-bis(4-nitro-2-(trifluoromethyl) 
phenyl)triaz-2-en-1-ide (16a). Method C. Green solid; yield 94%; mp 140–142 °C (MeOH); IR: 
3735, 3649, 3103, 2988, 1720, 1651, 1599, 1576, 1494, 1457 cm–1; 1H NMR (500 MHz, DMSO-
d6): δ (ppm) 1.15 (t, J = 7.2 Hz, 9H), 3.57 (q, J = 7.2 Hz, 6H), 3.78 (s, 3H), 6.65 (d, J = 14.4 Hz, 
1H), 7.18 (d, J = 14.4 Hz, 1H), 7.88–7.95 (m, 2H), 8.21–8.28 (m, 2H), 8.31–8.37 (m, 2H); 13C 
NMR (126 MHz, DMSO-d6): δ (ppm) 7.5, 52.5, 54.0, 116.8, 119.4 (q, J = 30 Hz), 122.5, 122.9 
(q, J = 6 Hz), 123.7 (q, J = 273 Hz), 127.5, 139.8, 145.7, 158.3, 163.7; HRMS (ESI+) m/z for 
C10H20NO2
+ [M]+: calcd 186.1489, found 186.1488; HRMS (ESI–) m/z for C14H6F6N5O4– [M]–: 
422.0329, found 422.0332. Anal. calcd for C24H26F6N6O6: C, 47.37; H, 4.31; N, 13.81. Found: C, 
47.30; H, 4.07; N, 13.84. 
3-Ethoxy-N,N,N-triethyl-3-oxoprop-1-en-1-aminium 1,3-bis(4-nitro-2-(trifluoromethyl) 
phenyl)triaz-2-en-1-ide (17a). Method C. Green solid; yield 92%; mp 128–130 °C (EtOH); IR: 
3085, 2948, 1715, 1649, 1596, 1574, 1494, 1455, 1436, 1396 cm–1; 1H NMR (500 MHz, DMSO-
d6): δ (ppm) 1.15 (t, J = 7.1 Hz, 9H), 1.27 (t, J = 7.1 Hz, 3H), 3.57 (q, J = 7.1 Hz, 6H), 4.24 (q, J 
= 7.1 Hz, 2H), 6.64 (d, J = 14.4 Hz, 1H), 7.16 (d, J = 14.4 Hz, 1H), 7.88–7.93 (m, 2H), 8.22–
8.27 (m, 2H), 8.31–8.35 (m, 2H); 13C NMR (126 MHz, DMSO-d6): δ (ppm) 7.5, 13.9, 54.0, 61.5, 
116.8, 119.4 (q, J = 30 Hz), 122.8, 122.9 (q, J = 6 Hz), 123.7 (q, J = 273 Hz), 127.5, 139.7, 
145.6, 158.6, 163.3; HRMS for C11H22NO2 [M]
+: calcd 200.1645, found 200.1644; HRMS (ESI–
) m/z for C14H6F6N5O4
– [M]–: calcd 422.0329, found 422.0332. Anal. calcd for C25H28F6N6O6: C, 
48.23; H, 4.53; N, 13.50. Found: C, 48.19; H, 4.27; N, 13.45. 
Potassium 1,3-bis(4-nitro-2-(trifluoromethyl)phenyl)triaz-2-en-1-ide (19a). Method D. 
Violet solid; yield 93%; mp 295–297 °C (MeCN/H2O); IR: 3112, 2114, 1733, 1715, 1601, 
15831505, 1465, 1436, 1415 cm–1; 1H NMR (500 MHz, DMSO-d6): δ (ppm) 7.88–7.96 (m, 2H), 
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8.23–8.30 (m, 2H), 8.32–8.40 (m, 2H); 13C NMR (126 MHz, DMSO-d6): δ (ppm) 117.0, 119.5 
(q, J = 30 Hz), 122.9 (q, J = 6 Hz), 123.7 (q, J = 273 Hz), 127.6, 140.0, 157.9; HRMS (ESI–) 
m/z for C14H6F6N5O4
– [M]–: calcd 422.0329, found 422.0327. Anal. calcd for C14H6F6KN5O4 × 
0.5 H2O: calcd C, 35.75; H, 1.50; N, 14.89; found: C, 35.74; H, 1.38; N, 14.73. 
Bacterial strains and growth conditions. Acinetobacter baumannii ATCC 19606, A. 
baumannii ATCC BAA-1605, Bacilus subtilis subsp. subtilis ATCC 6051, Klebsiella 
pneumoniae ATCC 13882, K. pneumoniae ATCC 700603, Pseudomonas aeruginosa ATCC 
27853 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, 
USA). Methicilin resistant Staphylococcus aureus (MRSA) USA300 was obtained from the 
culture collection of Professor C. G. Dowson (Warwick). Escherichia coli D22, E. coli N43 
CGSC 5583 and P. aeruginosa PA0001 were generously donated from the strain collection of 
Biota Ltd. Saccharomyces cerevisiae wild strain, Streptococcus pneumoniae R6, Vancomycin 
resistant Enterococcus faecalis (VREF) 501, Escherichia coli DH10β (Invitrogen) 
pHuLUC3/DH10β, MRSA wild strain 1653 and Mycobacterium smegmatis MC2 155 were 
obtained from the culture collection of Professor C. G. Dowson (Warwick). The direct colony 
suspension method described by the Clinical and Laboratory Standards Institute (CLSI) was used 
for inoculum preparation.41 Inoculum suspensions were prepared from isolated colonies selected 
from a 20 h to 24 h growth (96 h in case of M. smegmatis MC2 155) on tryptic soy agar (TSA) 
(A. baumannii ATCC 19606, A. baumannii ATCC BAA-1605, K. pneumoniae ATCC 13882, K. 
pneumoniae ATCC 700603, M. smegmatis MC2 155), Luria broth (LB) agar (E. coli DH10β, E. 
coli D22, E. coli N43 CGSC 5583, P. aeruginosa ATCC 27853, P. aeruginosa PA0001), yeast 
extract Peptone (YEP) agar (S. cerevisiae wild strain) and Brain-Heart Infusion (BHI) agar 
 32 
supplemented with 5% (v/v) sheep blood (Thermo Scientific) (MRSA USA300, MRSA wild 
strain 1653, S. pneumoniae R6, VREF 501).  
Determination of Minimal-Inhibitory Concentrations (MICs) and Minimal-Bactericidal 
Concentrations (MBCs). All MIC determinations were performed in polystyrene 96-well plates 
(Falcon) covered with seals (4titude, ABgene, Excel Scientific), with at least one duplicate. 
Growth was recorded using a plate reader (BMG Labtech Clario star, Thermo Scientific 
Varioskan Flash or Labsystems iEMS Reader MF). MICs were determined in accordance with 
the microdilution procedure recommended by EUCAST.42 The MICs for E.coli strains, MRSA 
USA300 and Bacilus subtilis ATCC 6051 were determined using LB broth. The final bacterial 
inoculum was 2×104 CFU/mL and the results were read after 18–20 h aerobic incubation at 37 
°C. The same protocol, but with a final bacterial inoculum of 3×104 CFU/mL, was used for P. 
aeruginosa strains and the MRSA wild-type strain. The MICs against A. baumannii and K. 
pneumoniae strains were determined using TSB broth, with a final bacterial inoculum of 3×104 
CFU/mL. Inoculated microtiter plates were aerobically incubated for 18–20 h at 37 °C. We also 
determined MICs for the tested compounds against S. pneumoniae R6, with a final bacterial 
inoculum of 5×104 CFU/mL, grown in BHI broth, the results being read after 18–20 h anaerobic 
incubation at 37 °C. The MICs against VREF 501 were determined using BHI broth. The final 
bacterial inoculum was 3×104 CFU/mL and the results were read after 18–20 h aerobic 
incubation at 37 °C. Microtiter plates inoculated with M. smegmatis MC2 155 in TSB broth 
(final inoculum 1×105 CFU/mL) were incubated aerobically for 94–98 h at 37 °C prior to 
recording the results. YEP broth was used for MIC determination against S. cerevisiae wild-type 
strain. The final inoculum cell density was 1×105 CFU/mL and the results were read after 18–20 
h aerobic incubation at 30 °C. The same protocols as above were used to determine MBCs for 
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the tested compounds. After the appropriate incubation time, the content of the wells at 
concentrations corresponding to the MIC, 2 × MIC, 4 × MIC, 8 × MIC (or above if necessary) 
were mixed, and a 10 μL portion was plated onto the corresponding (see Bacterial Strains and 
Growth Conditions) antibiotic-free agar plates, and incubated for 18–20 h (in case of M. 
smegmatis MC2 155 96 h) prior to visualization. When the MIC was above 128 μg/mL, MBC 
was not measured. 
Membrane integrity assay. Cell membrane damage was quantitatively determined with 
fluorescence measurements taken in a microplate reader (Varioskan Flash) using LIVE/DEAD® 
BacLightTM Bacterial Viability Kit (Invitrogen), repeated at least in triplicate. Suspension of 
bacterial cells, previously grown on the corresponding antibiotic-free agar plate (see Bacterial 
Strains and Growth Conditions), in 0.85% (w/v) NaCl solution, were divided into two equal 
portions and centrifuged at 4000g for 20 min. One pellet, representing live cells, was suspended 
in 0.85% (w/v) NaCl solution to yield an absorbance (OD600) of 0.2. The same amount of 
isopropanol (70% v/v) was added to the pellet, composed of dead bacterial cells. Both 
suspensions were incubated, with gentle shaking, for 1 h at room temperature. There were then 
harvested by centrifugation at 4000g for 20 min. Pellets were suspended in equal amount of 
0.85% (v/v) NaCl to yield a live cell suspension of OD600 0.2. Different proportions of live and 
dead cells were mixed to obtain cell suspensions containing different ratios of live and dead 
cells. 100 μL of these cell mixes were distributed into separate wells of a 96-well flat bottom 
black microtiter plate containing 3.2 μL DMSO in order to create a standard curve for 
comparison (see Supporting Information). Additionally, 100 μL of live cells were plated into 
wells containing the triazene solutions in 3.2 μL DMSO. The plate was incubated for 30 min at 
37 °C, then 100 μL dye solution (3 μL each component in 1 mL water) was added. After 15 min 
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incubation in the dark at room temperature, fluorescence was measured (excitation wavelength 
485 nm, emissions 530 nm and 630 nm). 
Synergistic effects of the triazenes with commercially available antibiotics. Synergy was 
determined by MIC measurement as described in the “Determination of Minimal-Inhibitory 
Concentrations (MICs) and Minimal-Bactericidal Concentrations (MBCs)” section. Selected 
ranges of different antibiotic concentrations (methicillin 0.25 μg/mL to 256 μg/mL, and 
vancomycin 0.25 μg/mL to 256 μg/mL) and the corresponding triazene (0.004 μg/mL to 0.25 
μg/mL) were tested in all possible combinations. 
Mutation frequency determination. Assays were carried out in triplicate. MRSA USA300 
inoculums were prepared in 15 mL LB broth as described above (see “Bacterial Strains and 
Growth Conditions” section). After a 18–20 h incubation at 37 °C, cultures were subjected to 
serial tenfold dilutions in sterile PBS buffer. For cell counting, 100 μL of each dilution was 
plated on BHI non-selective solid media. Cell numbers were determined following a 20–24 h 
incubation at 37 °C, by performing colony counts on the agar plates. For mutant cell counting 
100 μL of each dilution was plated onto selective BHI solid media containing active compound 
16a (0.03125 μg/mL, 0.0625 μg/mL, 0.09375 μg/mL or 0.125 μg/mL). Colony counts were then 
performed as above. The mutation rate value was calculated as the ratio between the resistant 
bacterial cell counts to the parental culture cell counts. 
Genomic DNA extraction. DNA was obtained from MRSA USA300 resistant strains 
obtained from the mutation rate assays. First, strains were continuously grown on selective BHI 
solid media plates for 20–24 h at 37 °C, with the appropriate concentration of the compound 16a, 
for 10 days. DNA extraction was performed using a Wizard Genomic DNA Purification Kit 
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(Promega) according to the manufacturer's instructions. As lytic enzymes, both lysozyme (60 μL, 
10 μg/mL) (Sigma Aldrich) and lysostaphin (60 μL, 1 μg/mL) (Sigma Aldrich) were used. 
Whole genome sequencing. 16a-Resistant MRSA USA300 strains were used. Short reads 
were generated using the Illumina MiSeq platform. The genome sequence of the closely related 
S. aureus USA300_TCH1516, available from the NCBI archive,43 was used as a reference. Short 
reads were aligned to the reference genome using SMALT.44 SNP’s were identified based on the 
criteria described by Harris and colleagues.45 Briefly, only bases with a Phred quality score 
above 50 were assessed (corresponding to a 99.999% base calling accuracy; www.phrap.org; 
www.illumina.com). A SNP was called if more than 75% of four or more reads (at least two 
reads aligning to the forward and reverse strand) supported the SNP. The site was otherwise 
identified as missing data. Short sequence insertions and deletions (indels) were identified both 
during the SMALT alignment process, and from using the program PINDEL46 to identify split 
reads i.e. where only part of a read mapped to the reference. 
On average, over 99.09% of reads mapped to the chosen reference. Variation was then filtered 
so that mutant isolates could be compared directly to the control isolate (MRSA USA300) used 
in the laboratory assays. 
In vitro cytotoxicity assay. The compound cytotoxicity was determined on the culture of 
primary normal human keratinocytes. Cells were grown as a monolayer culture in Dulbecco’s 
modified Eagle’s medium, DMEM (GIBCO), supplemented with 10% (v/v) fetal serum 
(GIBCO) at 37 °C with 5% (v/v) CO2. Cellular sensitivity to the most promising compounds was 
determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay.47 Cells were seeded in 96-well tissue culture plates (3000 cells/0.18 mL medium/well) and 
incubated for 24 h. The compounds were dissolved in DMSO and diluted with growth medium to 
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different concentrations, 20 μL of each dilution being added to each well. The highest DMSO % 
that we applied was 0.25%, which was not toxic to cells in the MTT assay. Each concentration 
was tested in quadruplicate. Following a 72 h incubation at 37 °C, the medium was aspirated, 
and 20 μg of MTT dye/0.04 mL medium was added to each well. Four hours later, formazan 
crystals were dissolved in DMSO (0.17 mL/well), and the plates were mechanically agitated for 
5 min. The optical density at 545 nm was determined on a microtiter plate reader (Awareness 
Technology Inc.), with each experiment being repeated three times. 
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Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.; HRMS, high-
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